7701:TSEShimadzu Corporation Analysis
Data as of 2026-03-14 - not real-time
¥3,868.00
Latest Price
4/10Risk
Risk Level: Medium
Executive Summary
Shimadzu is trading close to a key support level, with the short‑term moving average just beneath the current price and the longer‑term averages still above, suggesting a potential floor under the market. Technical momentum appears mixed: the RSI points to modest oversold pressure while the MACD shows a bearish divergence, and the histogram remains negative. Volatility is elevated, and the beta is low, indicating the stock moves less than the broader market. The price‑to‑earnings multiple sits well below the industry average, implying a valuation discount, and the dividend yield is modest but the payout ratio suggests sustainability. On the balance sheet, cash holdings are ample relative to debt, providing a strong liquidity cushion. Operating margins are healthy, and revenue is growing at a steady pace, supporting earnings stability. Analyst sentiment leans toward a buy recommendation, with a median target price notably higher than the current level. The combination of a defensive beta, solid cash position, and an attractive dividend makes the stock appealing for income‑focused investors. However, the recent bearish MACD signal and proximity to support caution against aggressive short‑term positioning. Overall, the fundamentals are sound, but the technicals suggest a watchful stance until price stabilizes.
In summary, Shimadzu presents a case of undervalued fundamentals backed by a sustainable dividend and low financial risk, while technical indicators advise patience. The stock’s defensive profile and growth prospects make it a compelling candidate for medium to long‑term accumulation.
In summary, Shimadzu presents a case of undervalued fundamentals backed by a sustainable dividend and low financial risk, while technical indicators advise patience. The stock’s defensive profile and growth prospects make it a compelling candidate for medium to long‑term accumulation.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- price hovering near support
- bearish MACD histogram
- RSI indicating oversold conditions
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- valuation discount to industry peers
- sustainable dividend payout
- low beta and strong cash position
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- steady revenue growth trajectory
- diversified product portfolio across scientific and medical segments
- robust balance sheet with low leverage
Key Metrics & Analysis
Financial Health
Revenue Growth7.00%
P/E Ratio20.0
Debt/Equity2.24
P/B Ratio2.1
Industry P/E33.7
Technical Analysis
TrendNeutral
RSI35.8
Support¥3,773.00
Resistance¥4,408.00
MA 20¥4,081.40
MA 50¥4,193.70
MA 200¥3,889.35
MACDBearish
VolumeIncreasing
Fear & Greed Index72.88
Valuation
Target Price¥5,094.55
Upside/Downside31.71%
GradeUndervalued
TypeValue
Dividend Yield1.73%
Risk Assessment
Beta0.33
Volatility28.99%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.